Improving Mesothelioma Therapy by Boosting Immune Responses to Mutations by Vaccination and by Immunogenic Chemotherapy
Abstract
This is the first annual report for award CA190450. The project examines neoantigen immune responses in (a) clinical samples and (b) mouse models. We have been significantly delayed in obtaining approval for human studies. HRPO approval was not obtained until recently (9-Jul-2021) and subsequently no other milestones for clinical aspects of the project have been met. We requested an extension of the award in May to accommodate this. We have successfully obtained ACURO approvals and commenced work on mapping and identifying simple (i.e. SNV) neoantigens in the mouse models. We have demonstrated that 44 percent of predicted neoantigens elicit T cell immune responses. Unfortunately, COVID related lockdowns have restricted some laboratory based aspects of identifying complex neoantigens. However, this has now been resolved. We are on track to complete Task 3 studies within timelines.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jul 01, 2021
- Accession Number
- AD1152667
Entities
People
- Alec J Redwood
- Bruce H. Robinson
- Jenette Creaney
Organizations
- University of Western Australia